Cargando…

Evaluation of the Optimal Manufacturing Protocols and Therapeutic Properties of Mesenchymal Stem/Stromal Cells Derived from Wharton’s Jelly

Wharton’s jelly (WJ) from the umbilical cord (UC) is a good source of mesenchymal stem/stromal cells (MSCs), which can be isolated and used in therapy. Current knowledge shows that even small changes in the cell environment may result in obtaining a subpopulation of cells with different therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Sypecka, Monika, Bzinkowska, Aleksandra, Sulejczak, Dorota, Dabrowski, Filip, Sarnowska, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820979/
https://www.ncbi.nlm.nih.gov/pubmed/36614096
http://dx.doi.org/10.3390/ijms24010652
_version_ 1784865588848361472
author Sypecka, Monika
Bzinkowska, Aleksandra
Sulejczak, Dorota
Dabrowski, Filip
Sarnowska, Anna
author_facet Sypecka, Monika
Bzinkowska, Aleksandra
Sulejczak, Dorota
Dabrowski, Filip
Sarnowska, Anna
author_sort Sypecka, Monika
collection PubMed
description Wharton’s jelly (WJ) from the umbilical cord (UC) is a good source of mesenchymal stem/stromal cells (MSCs), which can be isolated and used in therapy. Current knowledge shows that even small changes in the cell environment may result in obtaining a subpopulation of cells with different therapeutic properties. For this reason, the conditions of UC transportation, cell isolation, and cultivation and the banking of cells destined for clinical use should be unified and optimized. In this project, we tried various protocols for cell vs. bioptat isolation, banking, and transport in order to determine the most optimal. The most efficient isolation method of WJ-MSCs was chopping the whole umbilical matrix with a scalpel after vessel and lining membrane removal. The optimal solution for short term cell transportation was a multi-electrolyte fluid without glucose. Considering the use of WJ-MSCs in cell therapies, it was important to investigate the soluble secretome of both WJ bioptats and WJ-MSCs. WJ-MSCs secreted higher levels of cytokines and chemokines than WJ bioptats. WJ-MSCs secreted HGF, CCL2, ICAM-1, BDNF, and VEGF. Since these cells might be used in treating neurodegenerative disorders, we investigated the impact of cerebrospinal fluid (CSF) on WJ-MSCs’ features. In the presence of CSF, the cells expressed consecutive neural markers both at the protein and gene level: nestin, β-III-tubulin, S-100-β, GFAP, and doublecortin. Based on the obtained results, a protocol for manufacturing an advanced-therapy medicinal product was composed.
format Online
Article
Text
id pubmed-9820979
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98209792023-01-07 Evaluation of the Optimal Manufacturing Protocols and Therapeutic Properties of Mesenchymal Stem/Stromal Cells Derived from Wharton’s Jelly Sypecka, Monika Bzinkowska, Aleksandra Sulejczak, Dorota Dabrowski, Filip Sarnowska, Anna Int J Mol Sci Article Wharton’s jelly (WJ) from the umbilical cord (UC) is a good source of mesenchymal stem/stromal cells (MSCs), which can be isolated and used in therapy. Current knowledge shows that even small changes in the cell environment may result in obtaining a subpopulation of cells with different therapeutic properties. For this reason, the conditions of UC transportation, cell isolation, and cultivation and the banking of cells destined for clinical use should be unified and optimized. In this project, we tried various protocols for cell vs. bioptat isolation, banking, and transport in order to determine the most optimal. The most efficient isolation method of WJ-MSCs was chopping the whole umbilical matrix with a scalpel after vessel and lining membrane removal. The optimal solution for short term cell transportation was a multi-electrolyte fluid without glucose. Considering the use of WJ-MSCs in cell therapies, it was important to investigate the soluble secretome of both WJ bioptats and WJ-MSCs. WJ-MSCs secreted higher levels of cytokines and chemokines than WJ bioptats. WJ-MSCs secreted HGF, CCL2, ICAM-1, BDNF, and VEGF. Since these cells might be used in treating neurodegenerative disorders, we investigated the impact of cerebrospinal fluid (CSF) on WJ-MSCs’ features. In the presence of CSF, the cells expressed consecutive neural markers both at the protein and gene level: nestin, β-III-tubulin, S-100-β, GFAP, and doublecortin. Based on the obtained results, a protocol for manufacturing an advanced-therapy medicinal product was composed. MDPI 2022-12-30 /pmc/articles/PMC9820979/ /pubmed/36614096 http://dx.doi.org/10.3390/ijms24010652 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sypecka, Monika
Bzinkowska, Aleksandra
Sulejczak, Dorota
Dabrowski, Filip
Sarnowska, Anna
Evaluation of the Optimal Manufacturing Protocols and Therapeutic Properties of Mesenchymal Stem/Stromal Cells Derived from Wharton’s Jelly
title Evaluation of the Optimal Manufacturing Protocols and Therapeutic Properties of Mesenchymal Stem/Stromal Cells Derived from Wharton’s Jelly
title_full Evaluation of the Optimal Manufacturing Protocols and Therapeutic Properties of Mesenchymal Stem/Stromal Cells Derived from Wharton’s Jelly
title_fullStr Evaluation of the Optimal Manufacturing Protocols and Therapeutic Properties of Mesenchymal Stem/Stromal Cells Derived from Wharton’s Jelly
title_full_unstemmed Evaluation of the Optimal Manufacturing Protocols and Therapeutic Properties of Mesenchymal Stem/Stromal Cells Derived from Wharton’s Jelly
title_short Evaluation of the Optimal Manufacturing Protocols and Therapeutic Properties of Mesenchymal Stem/Stromal Cells Derived from Wharton’s Jelly
title_sort evaluation of the optimal manufacturing protocols and therapeutic properties of mesenchymal stem/stromal cells derived from wharton’s jelly
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820979/
https://www.ncbi.nlm.nih.gov/pubmed/36614096
http://dx.doi.org/10.3390/ijms24010652
work_keys_str_mv AT sypeckamonika evaluationoftheoptimalmanufacturingprotocolsandtherapeuticpropertiesofmesenchymalstemstromalcellsderivedfromwhartonsjelly
AT bzinkowskaaleksandra evaluationoftheoptimalmanufacturingprotocolsandtherapeuticpropertiesofmesenchymalstemstromalcellsderivedfromwhartonsjelly
AT sulejczakdorota evaluationoftheoptimalmanufacturingprotocolsandtherapeuticpropertiesofmesenchymalstemstromalcellsderivedfromwhartonsjelly
AT dabrowskifilip evaluationoftheoptimalmanufacturingprotocolsandtherapeuticpropertiesofmesenchymalstemstromalcellsderivedfromwhartonsjelly
AT sarnowskaanna evaluationoftheoptimalmanufacturingprotocolsandtherapeuticpropertiesofmesenchymalstemstromalcellsderivedfromwhartonsjelly